Hepatic venous outflow tract obstruction (HVOTO) is a rare cause of liver disease that tends to present in young adults with manifestations of portal hypertension. Although >80% of western HVOTO patients have an identifiable thrombophilic risk factor, most eastern HVOTO patients have idiopathic HVOTO and are more likely to present with both vena cava and hepatic vein occlusion.
1 Due to its low incidence worldwide, accurate estimates of the incidence and risk factors for HCC development in HVOTO are not well described. 2, 3 In a recent issue, Paul et al. report on the incidence of HCC in 413 HVOTO patients managed at a single referral centre in India over a 25-year time period. 4 The observed annual rate of HCC of only 0.35% per year is markedly lower compared to other more common causes of chronic liver disease (Table 1) . 5, 6 The authors reported that all of the patients with HCC had evidence of cirrhosis. In addition, vena cava occlusion and older subject age were more common in the patients with HCC compared to controls, but the small number of HCC cases precluded a multivariate analysis. Interestingly, serum AFP levels were increased in >80% at the time of HCC diagnosis as noted in prior studies. 3 Important inferences from this study include the much lower annual incidence of HCC in this large cohort of HVOTO patients (0.35%) compared to prior estimates (2-50%) reported in a recent meta-analysis. 7 Limitations of this retrospective case-control study include the lack of data on other established risk factors for HCC (i.e. anti-HBc status, smoking, alcohol consumption) and the potential for underreporting with only 17% of patients followed up for 5 years. Furthermore, establishing a diagnosis of HCC using contrast enhanced cross-sectional imaging criteria is particularly challenging in HVOTO patients due to their tendency to form arterialised liver nodules. The association between more extensive vena cava involvement with an apparent increased risk of HCC has been suggested in prior reports. 7 However, whether these vascular occlusion patterns simply increase the risk of HCC via accelerated fibrosis progression or through other mechanisms remain unclear. In summary, HVOTO patients with cirrhosis appear to be at increased risk of developing HCC. Serum AFP testing may prove particularly useful for HCC surveillance in 'high risk' HVOTO patients as has recently been reported in subjects with fibrotic congestive hepatopathy. 5 Additional prospective studies are now needed to determine if simple clinical parameters such as duration and type of HVOTO, subject age, and non-invasive estimates of fibrosis severity (i.e. magnetic resonance elastography) can further help identify 'high risk' HVOTO patients that may benefit from HCC surveillance. 
